Market Research Reports and Industry Reports

Multiple Sclerosis [2016]: Bulletin #3

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS



This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment landscape. Topics covered include; Roche reporting that a German patient with MS has developed progressive multifocal leukoencephalopathy (PML) following three years of treatment with Tysabri (natalizumab; Biogen) and one dose of Ocrevus (ocrelizumab); Merck Group announcing that the European Medicine Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for approval of Mavenclad (cladribine) for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity, and presenting new data on cladribines mechanism of action; and The European Medicines Agencys (EMA) provisionally restricting the use of Zinbryta (daclizumab; Biogen/AbbVie) due to a patients death from liver injury (fulminant liver failure), to patients with highly active relapsing disease that has failed to respond to certain other treatments, and to patients with rapidly evolving relapsing disease who cannot be treated with other medicines.



Business Questions:

Do KOLs believe that Ocrevus was the cause of this case of PML, or are other factors at play?
What impact will the news of this case of PML have on the prescribing of Ocrevus in the US, and will the news cause any change to patient monitoring requirements?
Was the FDA right to include a warning of the risk of PML on Ocrevus label, despite no cases of PML being seen in the pre-approval setting?
What has been the reaction to the recommendation for approval of cladribine in Europe, and will Merck Groups new data for cladribine dispel concerns about increased risk of malignancy?
How concerned are KOLs about patient segmentation and eligibility for cladribine?
Will Merck Group be able to leverage cladribines mechanism of action when it comes to differentiating it compared to other treatments?
Assuming full approval, where do KOLs see cladribine being used in the MS treatment paradigm, and which products are likely to lose market share?
Do KOLs believe that the EMAs decision to restrict the use of Zinbryta in Europe was justified?
What impact will the EMAs restriction have on the prescribing of Zinbryta in the US and Europe, and will the restriction be lifted any time soon?





Multiple Sclerosis [2016]: Bulletin #3

This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment

USD 1045View Report

Global Multiplex Biomarker Imaging Sales Market Report 2017

In this report, the global Multiplex Biomarker Imaging market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

USD 4000View Report

Global Multiple Sclerosis Market, Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) – Actual & Unmet (Potential)

Global Multiple Sclerosis Market, Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) Actual & Unmet (Potential) published by Renub Research on Multiple Sclerosis

USD 1599View Report

Global Primary Progressive Multiple Sclerosis Industry Market Research Report

Based on the Primary Progressive Multiple Sclerosis industrial chain, this report mainly elaborate the definition, types, applications and major players of Primary Progressive Multiple Sclerosis market in details. Deep analysis

USD 2960View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 1045
  • Enterprise Wide Licence    USD 2575
$ 1045

Reports Details

Published Date : Aug 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
pendik escort tuzla escort antalya escort bayan kartal escort
instagram takipci hilesi
paykasa bozdurma,paykasa bozdurma,astropay bozdurma,paykasa,paykasa,paykasa bozdurma,paykasa,astropay bozdurma,justin kart,bitcoin bozdurma,paykasa bozum,paykasa kart bozdurma,
beylikduzu escort,bahçeşehir escort,escort istanbul,istanbul escort,sex hikayeleri,pendik escort,
pedalebiellese.com,
istanbul escort bayan,besiktas escort,maltepe escort,kadikoy escort bayan,tekirdag escort bayan,findikzade escort,antalya escort bayan,ankara escort bayan,
Böcek İlaçlama,şehirler arası nakliyat,şehirler arası evden eve nakliyat,ofis taşıma,gebze evden eve nakliyat,kadıköy evden eve nakliyat,istanbul evden eve nakliyat,epoksi zemin,
ankara escort,ankara escort,ankara escort,
tipobet,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop